KRAS and cancer: Consistent with this, a previous report showed upregulation of SLC1A5/ASCT2 and glutamine metabolism genes in an isogenic KRAS mutant CRC cells [21], and another study revealed that the expression of the cystine‐glutamate exchanger SLC7A11/xCT is enhanced by KRAS mutations in different human cancers to cope with resulting oxidative stress [58].